Phase 2 clinical trial

Solana Beach, California — August 17, 2026 Artelo Biosciences, Inc. announced that the U.S. Patent and Trademark Office (USPTO)...

Austin, Texas — August 17, 2026 Faeth Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...

San Diego, California / Alderley Park, United Kingdom — August 14, 2026 Skye Bioscience, Inc. and Redx Pharma Limited...

San Diego, California, August 14, 2026 Phanes Therapeutics, Inc., a clinical-stage biotechnology company focused on immuno-oncology drug discovery and...

Toronto, Canada — August 14, 2026 Quantum BioPharma Ltd. reported continued progress on its lead therapeutic program Lucid-MS, following...

San Diego, California — August 14, 2026 Fate Therapeutics, Inc. has initiated the potentially registrational RECLAIM-LN Phase 2 clinical...

New York, New York, August,11, 2026 Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors, has announced...

OCALA, Fla., August 10, 2026 AIM ImmunoTech Inc. reported its second-quarter 2026 financial results and highlighted continued progress in...

SOLANA BEACH, Calif., August 10, 2026 Artelo Biosciences, Inc. announced that the first patient has been dosed in the...

DENVER, Colorado, August 10, 2026 Palisade Bio, Inc. announced its second-quarter 2026 financial results and provided a business update...